Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742736 · ClinicalTrials.gov registry record
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 13,000
- Enrollment target
NCT06742736 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 13,000 participants.
The verdict
NCT06742736 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 13,000 participants
- Enrollment target
Study Summary
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in the United States
Interventions
- DRUG BGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,000 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2024-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06742736
The ClinicalTrials.gov registry entry for NCT06742736 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BGF is the first listed.
NCT06742736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06742736 about?
NCT06742736 is a clinical study titled "EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)". A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in the United States
What is the current status of trial NCT06742736?
This trial is currently completed. The enrollment target is 13,000 participants. The study started on 2024-05-31. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT06742736?
The interventions under investigation include: BGF (DRUG).
Who is sponsoring clinical trial NCT06742736?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.